Latham & Watkins advises 4D Molecular Therapeutics on the deal. Astellas Pharma Inc. (TSE: 4503) and 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) have announced a license...
4D Molecular Therapeutics’ License Agreement with Astellas Pharma
4D Molecular Therapeutics’ $120 Million Common Stock Offering
Latham & Watkins advised 4D Molecular Therapeutics, while Cooley advised the underwriters for the offering. 4D Molecular Therapeutics, Inc. has announced that it priced an upsized...